Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Roche ...
MILFORD, Mass., PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) to ...
* Strongbridge Biopharma Plc - phase 3 sonics study is now more than 80 percent enrolled and we remain on track to fully enroll study during Q2 * Strongbridge Biopharma Plc - on schedule to commence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results